Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis

Published:2012-01 Issue:1 Volume:32 Page:15-27
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clinical Drug Investigation

Author:

Ali Shehzad,Paracha Noman,Cook Stuart,Giovannoni Gavin,Comi Giancarlo,Rammohan Kottil,Rieckmann Peter,Sørensen Per Soelberg,Vermersch Patrick,Greenberg Steven,Scott David A.,Joyeux Alexandre

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Reference19 articles.

1. Multiple Sclerosis

2. The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis

3. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis

4. B cells and multiple sclerosis

5. IMMUNOLOGY OF MULTIPLE SCLEROSIS

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis;Advances in Therapy;2023-09-30

2. Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review;Value in Health;2023-01

3. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis;Multiple Sclerosis and Related Disorders;2022-01

4. Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know;Neurology and Therapy;2020-02-13

5. Expert opinion on the use of cladribine tablets in clinical practice;Therapeutic Advances in Neurological Disorders;2020-01